Role of Genetics in ALS: Who Should Be TestedPremiere Date: Thursday, February 24, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- Psychological (apa)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, February 24, 2023
Note: Credit Is No Longer Available
|Jinsy A. Andrews, MD, MSc, FAAN (Moderator)
Director of Neuromuscular Clinical Trials, Department of Neurology
Columbia University Irving Medical Center
New York, NY
|Ammar Al-Chalabi, PhD, FRCP, DipStat
Professor of Neurology and Complex Disease Genetics
NIHR Senior Investigator
King's College London
Currently, 16,000-20,000 people are living in the United States with amyotrophic lateral sclerosis (ALS), with approximately 6,000 new patients diagnosed annually. Approved therapies can provide modest benefits in survival and quality of life (QoL), but there is no cure for ALS. Recent discoveries of genes contributing to disease risk have motivated the development of genetic testing that can provide diagnostic support, prognostic information, and eligibility for participation in clinical trials of emerging therapies. However, there is little consensus on how and when to employ genetic testing.
Given that the genetic landscape of ALS is rapidly changing, clinicians must be acquainted with recent advances and best practices. Join Dr. Andrews and Dr. Al-Chalabi in part 2 of this CMEOutfitter’s snack series as they discuss the utility of genetic testing in ALS.
At the end of this CE activity, participants should be able to:
- Employ genetic testing in patients with ALS based on the knowledge of genetic pathophysiology of ALS.
Supported by an educational grant from Biogen MA, Inc.
Adult neurologists, geneticists, genetic counselors; primary care physicians, PAs, nurse practitioners, nurses, physical therapists, occupational therapists, otolaryngologists
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Andrews reports the following financial relationships:
Consultant: AL-S Pharma AG; Amylyx Pharmaceuticals Inc.; Biogen Idec; Cytokinetics; Denali Therapeutics; Neurosense Therapeutics; Orphazyme; and Wave Life Sciences
Research Support: Alexion Pharmaceuticals, Inc.;AZTherapies Inc.; Biogen Idec; Biohaven Pharmaceuticals; Clene Nanomedicine, Inc.; Cytokinetics; Healey Center at Massachusetts General Hospital; National Institutes of Health; Novartis AG; Orion; and Ra Pharmaceuticals, Inc.
Dr. Al-Chalabi reports the following financial relationships:
Consultant: (All paid to his institution) Amylyx; Apellis Pharmaceuticals, Inc.; Biogen; BrainStorm Cell Therapeutics, Inc.; Cytokinetics, Inc.; GlaxoSmithKline; Lilly; Mitsubishi Tanabe Pharma Corporation; Novartis; Orion Pharma; QurAlis Corporation; and Wave Life Sciences
Speakers Bureau: (All paid to his institution) Biogen and Cytokinetics, Inc.
The following Peer Reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).